

# Global Lung Cancer Treatment Market - 2025-2033

<https://marketpublishers.com/r/GBFB6542B9A7EN.html>

Date: May 2025

Pages: 168

Price: US\$ 4,350.00 (Single User License)

ID: GBFB6542B9A7EN

## Abstracts

### Overview

The global lung cancer treatment market size reached US\$ 32.64 billion in 2024 and is expected to reach US\$ 73.29 billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.

Lung cancer is a type of cancer that begins in the lungs, which are the two spongy organs in the chest responsible for breathing. It is characterized by the uncontrolled growth of abnormal cells in the lung tissue, which can form a tumor. Over time, these cancerous cells can spread (metastasize) to other parts of the body. Treatment options depend on the type, stage, and location of the lung cancer, as well as the patient's overall health.

### Market Dynamics: Drivers & Restraints

Rising advancements in lung cancer treatment are significantly driving the market growth

Targeted therapies focus on specific genetic mutations and molecular changes in cancer cells, making treatments more precise and effective. These therapies are less toxic than traditional chemotherapy and are used to treat cancers with specific mutations. For instance, Osimertinib (Tagrisso) is a targeted therapy used to treat non-small cell lung cancer (NSCLC) with an EGFR mutation. It is more effective than traditional chemotherapy, leading to better survival outcomes and fewer side effects. In 2024, Tagrisso generated 6,580 million in sales, demonstrating the market's growing demand for targeted therapies.

Immunotherapy boosts the body's immune system to fight cancer cells. It has shown

promising results, particularly in advanced stages of lung cancer, where it can help in prolonging life and even achieving remission. For instance, Pembrolizumab (Keytruda) and Nivolumab (Opdivo) are immune checkpoint inhibitors that block the PD-1 protein, allowing the immune system to target cancer cells more effectively. These drugs have been game-changers for patients with advanced NSCLC, leading to a significant market shift towards immunotherapy.

These advancements have led to a shift from traditional, broad-based treatments to more targeted, personalized therapies. This change not only improves treatment outcomes but also creates a larger market for new therapies and personalized treatment options. As more patients benefit from these innovations, the demand for advanced lung cancer treatments continues to rise, driving significant market growth.

Side effects associated with lung cancer treatments are hampering the market growth

Side effects associated with lung cancer treatments can hamper market growth by discouraging patients from undergoing treatment, limiting the effectiveness of therapies, and increasing the healthcare burden. While advancements in lung cancer treatments have improved survival rates, many therapies still come with significant side effects that can affect the quality of life, increase treatment costs, and slow patient adoption of newer therapies.

Chemotherapy is a standard treatment for lung cancer, especially in advanced stages. However, it is associated with several severe side effects, including nausea, fatigue, hair loss, immune suppression, and anemia. These side effects can significantly reduce patients' quality of life and lead to treatment discontinuation or delays, hampering the overall effectiveness of chemotherapy in managing the disease.

For instance, Cisplatin and Carboplatin, two common chemotherapy drugs used to treat lung cancer, can cause severe nausea, vomiting, and kidney damage. These side effects make chemotherapy challenging for patients, leading to hesitancy in using these drugs, especially for older or frail patients.

While targeted therapies are more specific and less toxic than chemotherapy, they still come with side effects that can discourage patients from continuing treatment. These side effects can include skin rashes, diarrhea, liver problems, and fatigue. Even though targeted therapies are highly effective in treating cancers with specific mutations, the adverse reactions can affect the market's growth potential.

## Epidemiology Analysis

The incidence of lung cancer is rising. As per DataM intelligence estimates, nearly 2.63 million prevalent cases are estimated worldwide in 2024. The region with the highest prevalence is the Asia-Pacific, accounting for 1.66 million cases. Lung cancer is one of the most common and lethal cancers worldwide. Its epidemiology is influenced by various factors, including smoking habits, environmental exposures, genetic predispositions, and access to early detection and treatment. While advancements in treatment have improved survival rates, challenges such as late-stage diagnosis, high treatment costs, and regional disparities in care continue to impact outcomes. Early detection, reduced smoking rates, and improvements in personalized treatments hold the key to reducing the burden of lung cancer worldwide.

## Pipeline Analysis

Top phase III pipeline products for lung cancer:

## Segment Analysis

The global lung cancer treatment market is segmented based on cancer type, treatment type, and region.

### Cancer Type:

The Non-Small Cell Lung Cancer (NSCLC) segment is expected to dominate the lung cancer treatment market with the highest market share

NSCLC offers a variety of treatment options, including surgery, chemotherapy, targeted therapies, immunotherapy, and a combination of these. The diversity of treatment methods caters to different stages (early vs. advanced) and specific genetic mutations or biomarkers within NSCLC, thus increasing its market potential. Many market players are continuously performing clinical trials for better treatment of NSCLC, which further boosts the segment growth.

For instance, in August 2024, Bayer announced that the first patient has been enrolled in the global Phase III SOHO-02 trial, an open-label, randomized, multicenter clinical trial, assessing the efficacy and safety of investigational agent BAY 2927088 as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC), whose tumors have activating HER2 mutations.

A major portion of lung cancer research and pharmaceutical R&D investments is focused on NSCLC, given its high prevalence and complex biology. This results in the continual development of newer drugs and treatment approaches, including combination therapies that increase treatment efficacy. Thus, rising FDA approvals for NSCLC are further driving the segment demand.

For instance, in August 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

### Geographical Analysis

North America is expected to hold a significant position in the global Lung cancer treatment market with the highest market share

North America, particularly the United States, has a significant burden of lung cancer cases, which drives the demand for lung cancer treatments. Lung cancer remains one of the most common cancers in the region, largely due to high smoking rates (though smoking rates have been declining), air pollution, and other risk factors like radon exposure.

For instance, according to the American Cancer Society's estimates for lung cancer in the US for 2025 are about 226,650 new cases of lung cancer (110,680 in men and 115,970 in women) and about 124,730 deaths from lung cancer (64,190 in men and 60,540 in women). This high incidence leads to increased demand for treatments and contributes to the region's large share of the global lung cancer treatment market.

The U.S. Food and Drug Administration (FDA) is one of the fastest regulators in terms of approving new therapies, including cancer treatments. FDA approval is often seen as a critical step in the global market entry for new treatments. North America benefits from early access to cutting-edge therapies as they are approved, enabling patients to access the most effective treatment options.

For instance, in December 2024, Xcovery Holdings, Inc., an oncology-focused pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA)

approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval marks an important advancement in providing a new first-line option for patients with ALK-positive NSCLC.

## Competitive Landscape

Top companies in the lung cancer treatment market include Merck & Co., Inc., Pfizer Inc., AstraZeneca, Amgen Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Takeda Pharmaceuticals U.S.A., Inc., Amneal Pharmaceuticals LLC., Genentech USA, Inc., Rigel Pharmaceuticals, Inc., Daiichi Sankyo, Inc. and among others.

## Why Purchase the Report?

**Pipeline & Innovations:** Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.

**Product Performance & Market Positioning:** Analyze product performance, market positioning, and growth potential to optimize strategies.

**Real-World Evidence:** Integrates patient feedback and data into product development for improved outcomes.

**Physician Preferences & Health System Impact:** Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.

**Market Updates & Industry Changes:** Covers recent regulatory changes, new policies, and emerging technologies.

**Competitive Strategies:** Analyzes competitor strategies, market share, and emerging players.

**Pricing & Market Access:** Reviews pricing models, reimbursement trends, and market access strategies.

**Market Entry & Expansion:** Identifies optimal strategies for entering new markets and partnerships.

**Regional Growth & Investment:** Highlights high-growth regions and investment

opportunities.

**Supply Chain Optimization:** Assesses supply chain risks and distribution strategies for efficient product delivery.

**Sustainability & Regulatory Impact:** Focuses on eco-friendly practices and evolving regulations in healthcare.

**Post-market Surveillance:** Uses post-market data to enhance product safety and access.

**Pharmacoeconomics & Value-Based Pricing:** Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global lung cancer treatment market report delivers a detailed analysis with 57 key tables, more than 46 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.

#### Target Audience 2024

**Manufacturers:** Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.

**Regulatory & Policy:** Compliance Officers, Government, Health Economists, Market Access Specialists.

**Technology & Innovation:** AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.

**Investors:** Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.

**Consulting & Advisory:** Healthcare Consultants, Industry Associations, Analysts.

**Supply Chain:** Distribution and Supply Chain Managers.

**Consumers & Advocacy:** Patients, Advocacy Groups, Insurance Companies.

Academic & Research: Academic Institutions.

## Contents

### 1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

### 2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Cancer Type
- 2.4. Snippet by Treatment Type
- 2.5. Snippet by Region

### 3. DYNAMICS

- 3.1. Impacting Factors
  - 3.1.1. Drivers
    - 3.1.1.1. Rising Advancements in Lung Cancer Treatment
    - 3.1.1.2. Increasing Incidence of Lung Cancer
    - 3.1.1.3. XX
  - 3.1.2. Restraints
    - 3.1.2.1. Side Effects of Current Treatments
    - 3.1.2.2. High Cost of Treatment
    - 3.1.2.3. XX
  - 3.1.3. Opportunity
    - 3.1.3.1. Advancements in Targeted and Personalized Therapy
    - 3.1.3.2. XX
  - 3.1.4. Impact Analysis

### 4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
  - 4.1.1. Emerging Pioneers and Prominent Players
  - 4.1.2. Established Leaders with Largest Marketing Brand
  - 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs

#### 4.3. Regulatory and Reimbursement Landscape

4.3.1. North America

4.3.2. Europe

4.3.3. Asia Pacific

4.3.4. Latin America

4.3.5. Middle East & Africa

#### 4.4. Porter's Five Forces Analysis

#### 4.5. Supply Chain Analysis

#### 4.6. Patent Analysis

#### 4.7. SWOT Analysis

#### 4.8. Pipeline Analysis

#### 4.9. Epidemiology Analysis

#### 4.10. Unmet Needs and Gaps

#### 4.11. Recommended Strategies for Market Entry and Expansion

#### 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts

#### 4.13. Pricing Analysis and Price Dynamics

#### 4.14. Key Opinion Leaders

### **5. LUNG CANCER TREATMENT MARKET, BY CANCER TYPE**

#### 5.1. Introduction

5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

5.1.2. Market Attractiveness Index, By Cancer Type

#### 5.2. Non-Small Cell Lung Cancer (NSCLC)\*

5.2.1. Introduction

5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

5.2.3. Adenocarcinoma

5.2.4. Squamous Cell Carcinoma

5.2.5. Large Cell (Undifferentiated) Carcinoma

5.2.6. Others

#### 5.3. Small Cell Lung Cancer (SCLC)

#### 5.4. Lung Carcinoid Tumors

#### 5.5. Others

### **6. LUNG CANCER TREATMENT MARKET, BY TREATMENT TYPE**

#### 6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

6.1.2. Market Attractiveness Index, By Treatment Type

- 6.2. Chemotherapy\*
  - 6.2.1. Introduction
  - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  - 6.2.3. Gemcitabine
  - 6.2.4. Docetaxel
  - 6.2.5. Etoposide
  - 6.2.6. Paclitaxel
  - 6.2.7. Others
- 6.3. Radiation Therapy
- 6.4. Targeted Therapy
  - 6.4.1. Tyrosine Kinase Inhibitors
  - 6.4.2. Antibody-Drug Conjugates (ADCs)
  - 6.4.3. Angiogenesis Inhibitors
  - 6.4.4. Others
- 6.5. Surgery
- 6.6. Others

## **7. LUNG CANCER TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES**

- 7.1. Introduction
  - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  - 7.1.2. Market Attractiveness Index, By Region
- 7.2. North America
  - 7.2.1. Introduction
  - 7.2.2. Key Region-Specific Dynamics
  - 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  - 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  - 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 7.2.5.1. U.S.
    - 7.2.5.2. Canada
    - 7.2.5.3. Mexico
- 7.3. Europe
  - 7.3.1. Introduction
  - 7.3.2. Key Region-Specific Dynamics
  - 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  - 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  - 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 7.3.5.1. Germany

7.3.5.2. UK

7.3.5.3. France

7.3.5.4. Spain

7.3.5.5. Italy

7.3.5.6. Rest of Europe

#### 7.4. Asia-Pacific

7.4.1. Introduction

7.4.2. Key Region-Specific Dynamics

7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

7.4.5.1. China

7.4.5.2. India

7.4.5.3. Japan

7.4.5.4. South Korea

7.4.5.5. Rest of Asia-Pacific

#### 7.5. South America

7.5.1. Introduction

7.5.2. Key Region-Specific Dynamics

7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

7.5.5.1. Brazil

7.5.5.2. Argentina

7.5.5.3. Rest of South America

#### 7.6. Middle East and Africa

7.6.1. Introduction

7.6.2. Key Region-Specific Dynamics

7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

## 8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

8.1. Competitive Overview and Key Market Players

8.2. Market Share Analysis and Positioning Matrix

8.3. Strategic Partnerships, Mergers & Acquisitions

8.4. Key Developments in Product Portfolios and Innovations

8.5. Company Benchmarking

## **9. COMPANY PROFILES**

### 9.1. Merck & Co., Inc.\*

#### 9.1.1. Company Overview

#### 9.1.2. Product Portfolio

##### 9.1.2.1. Product Description

##### 9.1.2.2. Product Key Performance Indicators (KPIs)

##### 9.1.2.3. Historic and Forecasted Product Sales

##### 9.1.2.4. Product Sales Volume

#### 9.1.3. Financial Overview

##### 9.1.3.1. Company Revenue

##### 9.1.3.2. Geographical Revenue Shares

##### 9.1.3.3. Revenue Forecasts

#### 9.1.4. Key Developments

##### 9.1.4.1. Mergers & Acquisitions

##### 9.1.4.2. Key Product Development Activities

##### 9.1.4.3. Regulatory Approvals, etc.

#### 9.1.5. SWOT Analysis

### 9.2. Pfizer Inc.

### 9.3. AstraZeneca

### 9.4. Amgen Inc.

### 9.5. Eli Lilly and Company

### 9.6. Bristol-Myers Squibb Company

### 9.7. Takeda Pharmaceuticals U.S.A., Inc.

### 9.8. Amneal Pharmaceuticals LLC.

### 9.9. Genentech USA, Inc.

### 9.10. Rigel Pharmaceuticals, Inc.

### 9.11. Daiichi Sankyo, Inc.

LIST NOT EXHAUSTIVE

## **10. ASSUMPTION AND RESEARCH METHODOLOGY**

### 10.1. Data Collection Methods

### 10.2. Data Triangulation

### 10.3. Forecasting Techniques

### 10.4. Data Verification and Validation

## **11. APPENDIX**

11.1. About Us and Services

11.2. Contact Us

## List Of Tables

### LIST OF TABLES

Table 1 Global Lung Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US\$ Billion)

Table 2 Global Lung Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US\$ Billion)

Table 3 Global Lung Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US\$ Billion)

Table 4 Global Lung Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US\$ Billion)

Table 5 Global Lung Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US\$ Billion)

Table 6 Global Lung Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US\$ Billion)

Table 7 Global Lung Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US\$ Billion)

Table 8 Global Lung Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US\$ Billion)

Table 9 Global Lung Cancer Treatment Market Value, By Region, 2022-2033 (US\$ Billion)

Table 10 North America Lung Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US\$ Billion)

Table 11 North America Lung Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US\$ Billion)

Table 12 North America Lung Cancer Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 13 South America Lung Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US\$ Billion)

Table 14 South America Lung Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US\$ Billion)

Table 15 South America Lung Cancer Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 16 Europe Lung Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US\$ Billion)

Table 17 Europe Lung Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US\$ Billion)

Table 18 Europe Lung Cancer Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Billion)

Table 19 Asia-Pacific Lung Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US\$ Billion)

Table 20 Asia-Pacific Lung Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US\$ Billion)

Table 21 Asia-Pacific Lung Cancer Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 22 Middle East and Africa Lung Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US\$ Billion)

Table 23 Middle East and Africa Lung Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US\$ Billion)

Table 24 Middle East and Africa Lung Cancer Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 25 Merck & Co., Inc.: Overview

Table 26 Merck & Co., Inc.: Product Portfolio

Table 27 Merck & Co., Inc.: Key Developments

Table 28 Pfizer Inc.: Overview

Table 29 Pfizer Inc.: Product Portfolio

Table 30 Pfizer Inc.: Key Developments

Table 31 AstraZeneca: Overview

Table 32 AstraZeneca: Product Portfolio

Table 33 AstraZeneca: Key Developments

Table 34 Amgen Inc.: Overview

Table 35 Amgen Inc.: Product Portfolio

Table 36 Amgen Inc.: Key Developments

Table 37 Eli Lilly and Company: Overview

Table 38 Eli Lilly and Company: Product Portfolio

Table 39 Eli Lilly and Company: Key Developments

Table 40 Bristol-Myers Squibb Company: Overview

Table 41 Bristol-Myers Squibb Company: Product Portfolio

Table 42 Bristol-Myers Squibb Company: Key Developments

Table 43 Takeda Pharmaceuticals U.S.A., Inc.: Overview

Table 44 Takeda Pharmaceuticals U.S.A., Inc.: Product Portfolio

Table 45 Takeda Pharmaceuticals U.S.A., Inc.: Key Developments

Table 46 Amneal Pharmaceuticals LLC.: Overview

Table 47 Amneal Pharmaceuticals LLC.: Product Portfolio

Table 48 Amneal Pharmaceuticals LLC.: Key Developments

Table 49 Genentech USA, Inc.: Overview

Table 50 Genentech USA, Inc.: Product Portfolio

- Table 51 Genentech USA, Inc.: Key Developments
- Table 52 Rigel Pharmaceuticals, Inc.: Overview
- Table 53 Rigel Pharmaceuticals, Inc.: Product Portfolio
- Table 54 Rigel Pharmaceuticals, Inc.: Key Developments
- Table 55 Daiichi Sankyo, Inc.: Overview
- Table 56 Daiichi Sankyo, Inc.: Product Portfolio
- Table 57 Daiichi Sankyo, Inc.: Key Developments

## List Of Figures

### LIST OF FIGURES

Figure 1 Global Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 2 Global Lung Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 3 Global Lung Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 4 Global Lung Cancer Treatment Market Share, By Region, 2024 & 2033 (%)

Figure 5 Global Lung Cancer Treatment Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)

Figure 6 Non-Small Cell Lung Cancer (NSCLC) Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 7 Small Cell Lung Cancer (SCLC) Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 8 Lung Carcinoid Tumors Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 9 Others Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 10 Global Lung Cancer Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)

Figure 11 Chemotherapy Treatment Type in Global Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 12 Radiation Therapy Treatment Type in Global Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 13 Targeted Therapy Treatment Type in Global Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 14 Surgery Treatment Type in Global Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 15 Others Treatment Type in Global Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 16 Global Lung Cancer Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 17 North America Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 18 North America Lung Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 19 North America Lung Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 20 North America Lung Cancer Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 21 South America Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 22 South America Lung Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 23 South America Lung Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 24 South America Lung Cancer Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 25 Europe Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 26 Europe Lung Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 27 Europe Lung Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 28 Europe Lung Cancer Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 29 Asia-Pacific Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 30 Asia-Pacific Lung Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 31 Asia-Pacific Lung Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 32 Asia-Pacific Lung Cancer Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 33 Middle East and Africa Lung Cancer Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 34 Middle East and Africa Lung Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 35 Middle East and Africa Lung Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 36 Merck & Co., Inc.: Financials

Figure 37 Pfizer Inc.: Financials

Figure 38 AstraZeneca: Financials

Figure 39 Amgen Inc.: Financials

Figure 40 Eli Lilly and Company: Financials

Figure 41 Bristol-Myers Squibb Company: Financials

Figure 42 Takeda Pharmaceuticals U.S.A., Inc.: Financials

Figure 43 Amneal Pharmaceuticals LLC.: Financials

Figure 44 Genentech USA, Inc.: Financials

Figure 45 Rigel Pharmaceuticals, Inc.: Financials

## Figure 46 Daiichi Sankyo, Inc.: Financials

## I would like to order

Product name: Global Lung Cancer Treatment Market - 2025-2033

Product link: <https://marketpublishers.com/r/GBFB6542B9A7EN.html>

Price: US\$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GBFB6542B9A7EN.html>